Company intelligence / Profile preview
Eddingpharm
Shanghai, Shanghai, Chinaeddingpharm.com ↗
- Ownership
- Private
- Employees
- ~750
- Development stage
- Other
01
Overview
Recently received regulatory approval for VASCEPA (Icosapent Ethyl) in Mainland China for cardiovascular risk reduction as of July 8, 2024
- Therapeutic areas
- GastroenterologyPulmonologyCardiovascularOncologyMetabolic DisordersHematologyInfectious Diseases
- Modalities
- Small molecules (including VASCEPA/Icosapent Ethyl)
- Industry
- Biotech
02
Drug pipeline
15 assets14 more assets in the full pipeline.
03
Partnerships
AmarinShionogi & Co., Ltd.multinational pharmaceutical companies
Beyond the preview
Go deeper on Eddingpharm.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Eddingpharm.